市場調查報告書
商品編碼
1496165
經皮血管成形術 (PTA) 全球市場(2024 年版):按產品類型、應用、最終用戶和地區、市場洞察和預測進行分析(2020-2030 年)Global Percutaneous Transluminal Angioplasty (PTA) Market (2024 Edition): Analysis By Product Type (Balloon Catheters, Stents, Guidewires, Others), By Application, By End User, By Region: Market Insights and Forecast (2020-2030) |
2020-2023年全球經皮血管成形術(PTA)市場規模年複合成長率為10.25%。2023年市場規模為29.2億美元,預計2030年將達69.5億美元。該市場的推動因素包括心血管疾病盛行率上升、技術進步、人口老化、意識增強、醫療基礎設施改善、有利的償付政策、微創手術的採用增加、醫療保健成本上升、醫療旅遊,這是由戰略性產業合作和其他因素。
根據世界心臟聯合會統計,全球仍有超過5億人患有心血管疾病,預計2021年死亡人數將達到2,050萬人,佔全球整體。心血管疾病,包括冠狀動脈疾病、周邊動脈疾病和心律不整,仍是全世界發病和死亡的主要原因。心血管疾病的快速增加對有效的微創治療方案(如 PTA)產生了巨大的需求,這種治療方案無需進行大手術即可恢復阻塞或狹窄動脈的血流。
人們對微創選擇的認知不斷提高,導致患者對 PTA 等手術的需求增加。患者通常更喜歡微創手術,因為它可以減少疼痛、減少疤痕並縮短恢復時間。此外,醫療保健提供者擴大採用 PTA 等微創技術作為 CVD 管理的標準做法。醫療技術和程序的進步使 PTA 程序更安全、更有效、更容易執行,並且獲得臨床醫生的認可。
藥物塗層球囊(DCB)技術是經皮血管成形術(PTA)球囊導管的重大進步。這些球囊塗有抗增殖藥物,例如紫杉醇或Sirolimus,在膨脹時會局部釋放到動脈壁。與傳統的無塗層球囊相比,這種標靶藥物傳輸可抑制平滑肌細胞增生並抑制新內膜增生,進而改善長期血管通暢性。 DCB 已證明可以有效降低血管再阻塞率和重複干涉的需要,特別是在複雜病變和小血管中。該技術是一種很有前途的方法,可以透過解決血管再阻塞(與血管成形術相關的主要挑戰之一)來改善 PTA 手術的結果。
血管內超音波(IVUS)和光同調斷層掃瞄(OCT)等先進影像設備在增強周邊動脈疾病(PAD)的治療方面發揮重要作用。 IVUS 和 OCT 提供周邊動脈的高解析度影像,可實現準確的病變評估和治療計劃。透過在 PTA 手術期間提供即時指導,IVUS 和 OCT 可以幫助最佳化球囊尺寸、支架放置和後擴張手術,改善 PAD 患者的手術結果並降低併發症的發生率。該功能是 PAD 治療的重大進步,為臨床醫生提供了寶貴的工具,以提高全球 PTA 市場的手術精度和患者照護。
精準醫學和個人化治療的進步目的是根據患者個體特徵(包括遺傳傾向、疾病表現型和反應概況)來客製 PTA 治療。生物標記引導的干涉措施、針對患者的治療流程和標靶藥物傳輸系統為最佳化治療結果並最大限度地減少 PTA 手術中的不利事件提供了機會。
本報告調查全球經皮血管成形術(PTA)市場,並提供了包括市場規模和預測、區域和細分市場分析以及主要趨勢和機會在內的資訊。
Azoth Analytics has released a research report titled "Global Percutaneous Transluminal Angioplasty (PTA) Market (2024 Edition)" which provides a complete analysis of the Global Percutaneous Transluminal Angioplasty (PTA) industry in terms of market segmentation by Product Type (Balloon Catheters, Stents, Guidewires Others), by Application (Coronary Artery Disease, Peripheral Artery Disease), by End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics) for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030.
The report analyses the Percutaneous Transluminal Angioplasty (PTA) Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom, Germany, France, Spain, China, India, Japan, South Korea). The Global Percutaneous Transluminal Angioplasty (PTA) market showcased growth at a CAGR of 10.25% during 2020-2023. The market was valued at USD 2.92 Billion in 2023 which is expected to reach USD 6.95 Billion in 2030. The global percutaneous transluminal angioplasty (PTA) market is driven by the rising prevalence of cardiovascular diseases, technological advancements, an aging population, growing awareness, improved healthcare infrastructure, favorable reimbursement policies, increased adoption of minimally invasive procedures, rising healthcare expenditure, medical tourism, and strategic industry collaboration.
According to World Heart Federation, more than half a billion people around the world continue to be affected by cardiovascular diseases, which accounted for 20.5 million deaths in 2021- close to a third of all deaths globally and an overall increase on the estimated 121 million CVD deaths. Cardiovascular diseases, including coronary artery disease, peripheral artery disease, and cardiac arrhythmias, continue to be leading causes of morbidity and mortality globally. This surge in cardiovascular conditions creates a greater demand for effective, minimally invasive treatment options like PTA, which restore blood flow in blocked or narrowed arteries without the need for major surgery.
The growing awareness of minimally invasive options has led to increased patient demand for procedures like PTA. Patients often prefer minimally invasive techniques due to their perceived advantages, including reduced pain, scarring, and recovery time. Also, Healthcare providers are increasingly adopting minimally invasive techniques like PTA as standard practice in the management of CVDs. Advances in medical technology and techniques have made PTA procedures safer, more effective, and easier to perform, leading to greater acceptance among clinicians.
Drug-coated balloon (DCB) technology represents a significant advancement in balloon catheters for percutaneous transluminal angioplasty (PTA). These balloons are coated with anti-proliferative drugs, such as paclitaxel or sirolimus, which are released locally into the arterial wall during inflation. This targeted drug delivery helps to inhibit smooth muscle cell proliferation and reduce neointimal hyperplasia, thereby improving long-term vessel patency compared to traditional uncoated balloons. DCBs have demonstrated efficacy in reducing restenosis rates and the need for repeat interventions, particularly in complex lesions or small vessels. This technology offers a promising approach to improving the outcomes of PTA procedures by addressing one of the primary challenges associated with angioplasty-restenosis.
Advanced imaging modalities, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), play a crucial role in enhancing the treatment of peripheral artery disease (PAD). IVUS and OCT provide high-resolution imaging of peripheral arteries, allowing for precise lesion assessment and treatment planning. By offering real-time guidance during PTA procedures, IVUS and OCT help optimize balloon sizing, stent placement, and post-dilation techniques, leading to improved procedural outcomes and reduced rates of complications in PAD patients. This feature represents a significant advancement in the treatment of PAD, providing clinicians with invaluable tools to enhance procedural precision and patient care in the global PTA market.
Advancements in precision medicine and personalized therapies aim to tailor PTA treatments to individual patient characteristics, including genetic predispositions, disease phenotypes, and response profiles. Biomarker-guided interventions, patient-specific treatment algorithms, and targeted drug delivery systems offer opportunities to optimize treatment outcomes and minimize adverse events in PTA procedures.
Scope of the Report:
List of Tables
Table A1: Global Impact of Macro Economic Factors, By Region
Table A2: United States Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2020-2023 (USD Million)
Table A3: United States Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2024-2030 (USD Million)
Table A4: United States Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2020-2023 (USD Million)
Table A5: United States Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2024-2030 (USD Million)
Table A6: United States Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2020-2023 (USD Million)
Table A7: United States Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2024-2030 (USD Million)
Table A8: Canada Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2020-2023 (USD Million)
Table A9: Canada Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2024-2030 (USD Million)
Table A10: Canada Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2020-2023 (USD Million)
Table A11: Canada Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2024-2030 (USD Million)
Table A12: Canada Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2020-2023 (USD Million)
Table A13: Canada Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2024-2030 (USD Million)
Table A14: Rest of Americas Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2020-2023 (USD Million)
Table A15: Rest of Americas Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2024-2030 (USD Million)
Table A16: Rest of Americas Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2020-2023 (USD Million)
Table A17: Rest of Americas Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2024-2030 (USD Million)
Table A18: Rest of Americas Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2020-2023 (USD Million)
Table A19: Rest of Americas Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2024-2030 (USD Million)
Table A20: United Kingdom Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2020-2023 (USD Million)
Table A21: United Kingdom Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2024-2030 (USD Million)
Table A22: United Kingdom Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2020-2023 (USD Million)
Table A23: United Kingdom Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2024-2030 (USD Million)
Table A24: United Kingdom Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2020-2023 (USD Million)
Table A25: United Kingdom Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2024-2030 (USD Million)
Table A26: Germany Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2020-2023 (USD Million)
Table A27: Germany Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2024-2030 (USD Million)
Table A28: Germany Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2020-2023 (USD Million)
Table A29: Germany Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2024-2030 (USD Million)
Table A30: Germany Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2020-2023 (USD Million)
Table A31: Germany Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2024-2030 (USD Million)
Table A32: France Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2020-2023 (USD Million)
Table A33: France Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2024-2030 (USD Million)
Table A34: France Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2020-2023 (USD Million)
Table A35: France Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2024-2030 (USD Million)
Table A36: France Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2020-2023 (USD Million)
Table A37: France Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2024-2030 (USD Million)
Table A38: Spain Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2020-2023 (USD Million)
Table A39: Spain Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2024-2030 (USD Million)
Table A40: Spain Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2020-2023 (USD Million)
Table A41: Spain Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2024-2030 (USD Million)
Table A42: Spain Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2020-2023 (USD Million)
Table A43: Spain Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2024-2030 (USD Million)
Table A44: Rest of Europe Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2020-2023 (USD Million)
Table A45: Rest of Europe Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2024-2030 (USD Million)
Table A46: Rest of Europe Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2020-2023 (USD Million
Table A47: Rest of Europe Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2024-2030 (USD Million)
Table A48: Rest of Europe Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2020-2023 (USD Million)
Table A49: Rest of Europe Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2024-2030 (USD Million)
Table A50: China Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2020-2023 (USD Million)
Table A51: China Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2024-2030 (USD Million)
Table A52: China Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2020-2023 (USD Million)
Table A53: China Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2024-2030 (USD Million)
Table A54: China Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2020-2023 (USD Million)
Table A55: China Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2024-2030 (USD Million)
Table A56: Japan Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2020-2023 (USD Million)
Table A57: Japan Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2024-2030 (USD Million)
Table A58: Japan Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2020-2023 (USD Million)
Table A59: Japan Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2024-2030 (USD Million)
Table A60: Japan Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2020-2023 (USD Million)
Table A61: Japan Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2024-2030 (USD Million)
Table A62: India Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2020-2023 (USD Million)
Table A63: India Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2024-2030 (USD Million)
Table A64: India Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2020-2023 (USD Million)
Table A65: India Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2024-2030 (USD Million)
Table A66: India Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2020-2023 (USD Million)
Table A67: India Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2024-2030 (USD Million)
Table A68: South Korea Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2020-2023 (USD Million)
Table A69: South Korea Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2024-2030 (USD Million)
Table A70: South Korea Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2020-2023 (USD Million)
Table A71: South Korea Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2024-2030 (USD Million)
Table A72: South Korea Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2020-2023 (USD Million)
Table A73: South Korea Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2024-2030 (USD Million)
Table A74: Rest of Asia-Pacific Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2020-2023 (USD Million)
Table A75: Rest of Asia-Pacific Percutaneous Transluminal Angioplasty (PTA) Market, By Product Type, By Value, 2024-2030 (USD Million)
Table A76: Rest of Asia-Pacific Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2020-2023 (USD Million)
Table A77: Rest of Asia-Pacific Percutaneous Transluminal Angioplasty (PTA) Market, By Application, By Value, 2024-2030 (USD Million)
Table A78: Rest of Asia-Pacific Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2020-2023 (USD Million)
Table A79: Rest of Asia-Pacific Percutaneous Transluminal Angioplasty (PTA) Market, By End User, By Value, 2024-2030 (USD Million)
Table A80: Medtronic PLC Key Company Financials, 2021-2023
Table A81: Terumo Corporation Key Company Financials, 2021-2023
Table A82: Cardinal Health Key Company Financials, 2021-2023
Table A83: Boston Scientific Key Financials, 2021-2023
Table A84: Teleflex Incorporated Key Financials, 2021-2022
Table A85: Johnson & Johnson Key Financials, 2021-2023
Table A86: Abbott Laboratories Key Financials, 2021-2023
Table A87: Stryker Corporation Key Company Financials, 2021-2023
Table A88: Becton Dickinson Key Company Financials, 2021-2023